medigraphic.com
Academia Mexicana de Neurología, A.C.

2011, Number 1

<< Back Next >>

Rev Mex Neuroci 2011; 12 (1)

Spinal cord invasion by a mycetamatous sporotrichosis

Gutiérrez MJL, Domínguez MR, Morales EM, Rossiere ENL, Reyes BG, Santos RA

Language: Spanish
References: 19
Page: 50-54
PDF size: 169.75 Kb.


ABSTRACT

Introduction: Subcutaneous or profound sporotrichosis is caused by the dimorphic fungus Sporothrix schenckii. It has a subacute or chronic course and involves skin and lymphatic system with rubbery lesions. A rare clinical variety is the mycetomatous or tumoral sporotrichosis. We present a case of chronic mycetomatous sporotrichosis with spinal invasion, neurological involvement and bilateral pleural effusion. Clinical case: A 39-year-old farmer with history of nonhealed cervical profound mycosis caused by sporothrix schenckii had chronic sensitive symptoms in pelvic limbs and developed a spinal cord transverse syndrome of five days duration. Laboratory tests showed leukocytosis, anemia and a negative HIV test. Cerebrospinal fluid (CSF) cytological and chemical aspects were normal and the CSF culture was negative. The biopsy showed inflammatory changes and the MRI spinal invasion and bone infiltration. Discussion: Sporotrichosis is the most common profound mycosis, but the mycetomatous variety is rare, occurring in less than 4% of sporotrichosis cases. It is characterized by the presence of several inflammatory granulomatous fistulized lesions that can simulate a mycetoma principally involving the lower limbs, a feature that contrasts with our patient because his lesions were in the dorsal region. There have been few cases of profound mycosis associated to spinal invasion described on the literature.


REFERENCES

  1. Manzur J, Díaz-Almeida J, Cortés M. Dermatología. 1a. Ed. La Habana: Ciencias Médicas; 2002.

  2. Ramos-E-Silva M, Vasconcelos C, Carneiro S, Cestari T. Sporotrichosis. Clin Dermatol 2007; 25: 181-7.

  3. Hektoen l, Perkins CF. Refractory subcutaneous Caused by sporothrix schenckii. A new Pathogenic fungus. J Exp Med 1900; 5: 77-89.

  4. López-Cepeda LD, Moreno-Agraz G, Padilla-Desgarennes MC. Esporotricosis facial y linfangítica en un adulto, tratado eficazmente con yoduro de potasio. Rev Cent Dermatol Pascua 2004; 13: 25-8.

  5. DaRosa AC, Scroferneker ML, Vettorato R, Gervini RL, Vettorato G, Weber A. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52: 451-9.

  6. Macotela-Ruiz E, Nochebuena-Ramos E. Esporotricosis en algunas comunidades rurales de la Sierra Norte de Puebla. Informe de 55 casos (Septiembre 1995-Diciembre 2005). Gac Méd Méx 2006; 142: 377-80.

  7. Conti-Diaz I. Esporotricosis. Rev Med Uruguay 1987; 3: 135-47.

  8. Rubio G, Sánchez G, Porras L, Alvarado Z. Esporotricosis: prevalencia, perfil clínico y epidemiológico en un centro de referencia en Colombia. Rev Iberoam Micol 2010; 27: 75-9.

  9. Vázquez TO, Campos RT, González SN, García Camacho G. Esporotricosis micetomatoide. Rev Enf Inf Ped 2001; 15: 54-5.

  10. Beketi AK. Cranial and cervical vertebral mycetoma. Report of three cases. Neurochirurgie 2005; 51: 471-5.

  11. Arbab MA, el Hag IA, Abdul Gadir AF, Siddik H el-R. Intraspinal mycetoma: report of two cases. Am J Trop Med Hyg 1997; 56: 27-9.

  12. Mahajan VK, Sharma NL, Sharma RC, Gupta ML, Garg G, Kanga AK. Cutaneous sporotrichosis in Himachal Pradesh, India. Mycoses. 2005; 48: 25-31.

  13. Arenas R. Sporotrichosis. In: Merz WG, Hay R (eds.). Topley & Wilsongs. Microbiology and Microbial infections. 10th Ed. London: Hodder- Arnold; 2005, p. 367-84.

  14. González-Ochoa A, Figueroa E. Polisacaridos del Sporotrichum schenckii. Dados eptidegicos. Intradermoreacción en el diagnóstico de la esporotricose. Rev Inst Salubr Enferm Trop 1947; 8: 143-53.

  15. Bernardes-Engemann A. Improved enzyme-linked immunosorbent assay using the Ss-CBF antigen for the serodiagnosis of several clinical forms of sporotrichosis. Med Mycol 2005; 43: 487-93.

  16. Sterling J, Heymann W. Potassium iodide in dermatology: A 19th century drug for the 21st century uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 200; 43: 691-7.

  17. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61: 27-37.

  18. Baroni A, Palla M, Lovene M, Faccenda F, Aiello F, Puca R, Satriano R. Sporotrichosis: success of itraconazole treatment. Skinmed 2007; 6: 41-4.

  19. Bonifaz A, Fierro L, Saúl A, Ponce R. Cutaneous sporotrichosis. Intermittent treatment (pulses) with Itraconazole. Eur J Dermatol 2008; 18: 61-4.




2020     |     www.medigraphic.com